UK's Aptamer H1 revenue rises on new pharma contracts

Aptamer

25/03/2026 07:22

Corrects Key Details table to say company reported loss per share and loss per basic share

Overview

UK synthetic binder developer's H1 revenue grew 27% yr/yr, reflecting increased commercial traction

Adjusted EBITDA loss narrowed to £1.0 mln as revenue improved and costs remained lean

Company launched Accelerated Book Build to raise at least £3.75 mln, extending cash runway to 2028

Outlook

Aptamer expects cash runway to extend through to 2028 after recent fundraising

Company aims to convert asset portfolio into recurring royalty and licensing revenues

Aptamer targets in vivo data for radiopharmaceutical pipeline by end of 2026

Increased manufacturing capacity and quality audits to support supply of licensed assets and improve margins

Result Drivers

PHARMA CONTRACTS - Revenue growth driven by new and repeat fee-for-service contracts with top pharmaceutical companies, including a major contract win in radioligand therapy

LICENSING REVENUE - Initial licensing payments received from out-licensed Optimer assets to Twist Bioscience and Alphazyme, with additional licensing discussions underway

Company press release: ID:nRSY0113Ya

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
H1 EPS
-GBp 0.04
H1 Adjusted EBITDA
-GBP 1.02 mln
H1 Basic EPS
-GBp 0.04
H1 EBIT
-GBP 1.24 mln
H1 Gross Profit
GBP 460,000


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

 (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)